Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Germany”

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 DiabetesRecruiting
NCT07743450Phase 3Updated Aug 14, 2026
Sponsor: Ascletis Pharma (China) Co., Limited
Obesity · Overweight · Chronic Weight Management · Type 2 Diabetes Mellitus
United States, Czechia, Germany, Greece, Poland +1 more
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)Recruiting
NCT06312176Phase 3Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Breast Neoplasms
United States, Argentina, Australia, Belgium, Brazil +35 more
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's LymphomaRecruiting
NCT06806033Phase 2Updated Aug 14, 2026
Sponsor: Hoffmann-La Roche
B-Cell Non-Hodgkins Lymphoma
United States, Australia, Canada, France, Germany +2 more
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of ProgressionActive Not Recruiting
NCT05797610Phase 3Updated Aug 14, 2026
Sponsor: Hoffmann-La Roche
Primary IgA Nephropathy
United States, Argentina, Australia, Brazil, Canada +16 more
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)Active Not Recruiting
NCT06074588Phase 3Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer (NSCLC)
United States, Australia, Brazil, Canada, Chile +20 more
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's DiseaseActive Not Recruiting
NCT03105102Phase 3Updated Aug 14, 2026
Sponsor: AbbVie
Crohn's Disease
United States, Argentina, Australia, Austria, Belarus +42 more
A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged SeizuresEnrolling By Invitation
NCT05076617Phase 3Updated Aug 14, 2026
Sponsor: UCB Biopharma SRL
Stereotypical Prolonged Seizures
United States, Australia, Bulgaria, China, Czechia +7 more
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve FailureRecruiting
NCT06557798N/AUpdated Aug 14, 2026
Sponsor: The Leeds Teaching Hospitals NHS Trust
Aortic Valve Stenosis
Denmark, Finland, France, Germany, Israel +6 more
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCRecruiting
NCT06627647Phase 3Updated Aug 14, 2026
Sponsor: AstraZeneca
Non-squamous Non-small Cell Lung Cancer
United States, Argentina, Australia, Belgium, Brazil +20 more
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) TherapyRecruiting
NCT07226765Phase 3Updated Aug 14, 2026
Sponsor: Amgen
Obstructive Sleep Apnea
United States, Australia, Brazil, Canada, Czechia +6 more
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)Recruiting
NCT06667700Phase 3Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Coronavirus Disease (COVID-19)
United States, Argentina, Brazil, Bulgaria, Colombia +19 more
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesRecruiting
NCT07351058Phase 3Updated Aug 14, 2026
Sponsor: Hoffmann-La Roche
Obesity or Overweight · Type 2 Diabetes Mellitus
United States, Argentina, Australia, Brazil, Canada +15 more
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone LymphomaRecruiting
NCT06149286Phase 3Updated Aug 14, 2026
Sponsor: Regeneron Pharmaceuticals
Relapsed/Refractory Follicular Lymphoma · Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
United States, Australia, Austria, Belgium, Brazil +13 more
Master Framework For Relapse or Refractory Acute Myeloid LeukemiaRecruiting
NCT06459024N/AUpdated Aug 14, 2026
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Acute Myeloid Leukemia, in Relapse · Acute Myeloid Leukemia Refractory
Germany, Italy, Lithuania, Poland, Romania +1 more
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsRecruiting
NCT06772623Phase 1, Phase 2Updated Aug 14, 2026
Sponsor: AbbVie
Non Small Cell Lung Carcinoma
United States, Australia, Belgium, China, France +10 more
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.Recruiting
NCT07028853Phase 3Updated Aug 14, 2026
Sponsor: Pfizer
Metastatic Castration Sensitive Prostate Cancer (mCSPC) · Hormone Sensitive Prostate Cancer · Prostate Cancer · Cancer of the Prostate
United States, Argentina, Australia, Belgium, Brazil +21 more
Rescue of Nephrons With ALE.F02 (RENAL-F02)Recruiting
NCT06047171Phase 2Updated Aug 14, 2026
Sponsor: Alentis Therapeutics AG
Glomerulonephritis Rapidly Progressive
Czechia, Denmark, France, Germany, Italy +5 more
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)Recruiting
NCT07060807Phase 3Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Breast Neoplasms
United States, Argentina, Australia, Brazil, Canada +21 more
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).Recruiting
NCT06646276Phase 3Updated Aug 14, 2026
Sponsor: Bristol-Myers Squibb
Extensive-Stage Small Cell Lung Cancer
United States, Argentina, Australia, Austria, Belgium +21 more
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid ArthritisCompleted
NCT05814627Phase 3Updated Aug 14, 2026
Sponsor: AbbVie
Rheumatoid Arthritis
United States, Argentina, Belgium, Brazil, Bulgaria +20 more
A Study to Assess Disease Activity in Adolescent and Adult Participants With Atopic Dermatitis Who Receive Oral Upadacitinib Tablets in a Real-World SettingActive Not Recruiting
NCT05139836N/AUpdated Aug 14, 2026
Sponsor: AbbVie
Atopic Dermatitis
Germany
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DMActive Not Recruiting
NCT06845202Phase 1, Phase 2Updated Aug 14, 2026
Sponsor: Alnylam Pharmaceuticals
Obese or Overweight Healthy Volunteers · Type 2 Diabetes Mellitus (T2DM)
United States, Argentina, Canada, Chile, Germany +1 more
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary FibrosisNot Yet Recruiting
NCT07441408Phase 3Updated Aug 14, 2026
Sponsor: Bristol-Myers Squibb
Pulmonary Fibrosis
United States, Argentina, Australia, Belgium, Brazil +22 more
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With CardiomyopathyRecruiting
NCT07052903Phase 3Updated Aug 14, 2026
Sponsor: Alnylam Pharmaceuticals
Transthyretin Amyloidosis With Cardiomyopathy
United States, Argentina, Australia, Austria, Belgium +30 more
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)Active Not Recruiting
NCT05878769Phase 3Updated Aug 14, 2026
Sponsor: Hoffmann-La Roche
Chronic Obstructive Pulmonary Disease
United States, Argentina, Australia, Austria, Belgium +35 more

Previous page Next page